Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
- 18 August 2004
- Vol. 101 (5), 894-904
- https://doi.org/10.1002/cncr.20480
Abstract
BACKGROUND The widespread use of prostate‐specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA‐based screening has resulted in a stage migration to more organ‐confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so‐called “normal” range. METHODS The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA‐based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high‐grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 111 references indexed in Scilit:
- Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0–2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?Urologic Oncology, 2004
- Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/MlJournal of Urology, 2003
- Characteristics of prostate cancers detected at low PSA levelsThe Prostate, 2003
- Screening for Prostate Cancer in High Risk PopulationsJournal of Urology, 2002
- Androgen Receptor Length Polymorphism Associated with Prostate Cancer Risk in Hispanic MenJournal of Urology, 2002
- DIGITAL RECTAL EXAMINATION FOR DETECTING PROSTATE CANCER AT PROSTATE SPECIFIC ANTIGEN LEVELS OF 4 NG./ML. OR LESSJournal of Urology, 1999
- Dietary Fat and Prostate Cancer Progression and SurvivalEuropean Urology, 1999
- Biological Variation of Total, Free and Percent Free Serum Prostate Specific Antigen Levels in Screening VolunteersJournal of Urology, 1997
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987